FMC's Dividend In Danger? Analyst Warns Of Debt Pressures And Credit Downgrade Risks
Written by Emily J. Thompson, Senior Investment Analyst
Source: Benzinga
FMC Corporation's Financial Performance: FMC reported fourth-quarter results with adjusted EPS of $1.79, surpassing estimates, but sales of $1.22 billion fell short of expectations. The company has a weak first-quarter outlook and forecasts lower adjusted EPS and revenue for FY25 compared to analyst estimates.
Analyst Downgrades and Stock Impact: Analysts from BofA Securities and RBC Capital downgraded FMC's stock due to concerns over competition, limited EBITDA growth, and potential dividend cuts, leading to a significant drop in share price by nearly 35%.
Analyst Views on FMC
Wall Street analysts forecast FMC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FMC is 19.08 USD with a low forecast of 13.00 USD and a high forecast of 28.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Analyst Rating
3 Buy
10 Hold
1 Sell
Hold
Current: 16.020
Low
13.00
Averages
19.08
High
28.00
Current: 16.020
Low
13.00
Averages
19.08
High
28.00
About FMC
FMC Corporation is a global agricultural sciences company engaged in providing farmers solutions that increase the productivity and resilience of their land. The Company’s crop protection solutions, including biologicals, crop nutrition, digital and precision agriculture, enable growers and crop advisers to address their challenges economically while protecting the environment. Its portfolio consists of three major pesticide categories: insecticides, herbicides and fungicides. The majority of its product lines consist of insecticides and herbicides, and it has a portfolio of fungicides mainly used in high-value crop segments. Its insecticides are used to control a wide spectrum of pests, while its herbicide portfolio primarily targets a large variety of difficult-to-control weeds. In addition, it is also investing in its Plant Health program, which includes biologicals, crop nutrition, and seed treatment products. Biological technologies serve as complements to its synthetic products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
